Page last updated: 2024-12-09

2-(1,3-benzothiazol-2-ylamino)-4-(methylthio)butanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(1,3-benzothiazol-2-ylamino)-4-(methylthio)butanoic acid, also known as **BTSA**, is a synthetic compound that acts as a **potent and selective inhibitor of the enzyme methionine adenosyltransferase (MAT)**.

**What is Methionine Adenosyltransferase (MAT)?**

MAT is a crucial enzyme involved in the biosynthesis of S-adenosyl methionine (SAM), a universal methyl donor that plays a critical role in numerous metabolic pathways. SAM is essential for various processes like:

* **DNA methylation**
* **Protein methylation**
* **Neurotransmitter synthesis**
* **Lipid metabolism**

**Why is BTSA Important for Research?**

**1. Understanding the Role of MAT:**
* BTSA, as a specific inhibitor of MAT, allows researchers to study the role of MAT and SAM in various biological processes. By inhibiting MAT activity, researchers can investigate the consequences of decreased SAM levels and gain insights into the regulatory mechanisms of these pathways.

**2. Developing New Therapeutics:**

* Given the diverse functions of SAM, dysregulation of MAT activity is linked to several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.
* BTSA, as a selective MAT inhibitor, holds therapeutic potential for these conditions by modulating SAM levels and their associated metabolic pathways.
* Researchers are exploring the use of BTSA and its derivatives as potential drugs for specific conditions.

**3. Studying Cellular Metabolism:**

* BTSA can be a valuable tool for investigating the metabolic pathways that rely on SAM.
* Researchers can use BTSA to study the effects of altered SAM levels on various cellular processes, including cell growth, differentiation, and apoptosis.

**4. Potential for Drug Development:**

* The selectivity and potency of BTSA make it an attractive starting point for developing novel drugs targeting MAT activity.
* Researchers can modify the structure of BTSA to improve its pharmacokinetic properties and optimize its therapeutic potential.

**In summary, BTSA is a valuable research tool for understanding the role of MAT in cellular processes, developing new therapeutic strategies for diseases linked to SAM dysregulation, and investigating the intricacies of cellular metabolism.**

Cross-References

ID SourceID
PubMed CID651739
CHEMBL ID1453118
CHEBI ID105801
SCHEMBL ID23273787

Synonyms (26)

Synonym
OPREA1_595965
smr000001304
BAS 00280985
MLS000031314
2-(benzothiazol-2-ylamino)-4-methylsulfanyl-butyric acid
OPREA1_090519
CHEBI:105801
AKOS000301332
2-(1,3-benzothiazol-2-ylamino)-4-methylsulfanylbutanoic acid
436810-97-8
A826394
2-(benzo[d]thiazol-2-ylamino)-4-(methylthio)butanoic acid
2-(benzothiazol-2-ylamino)-4-methylsulfanylbutyric acid
HMS2356H11
FT-0644676
2-(benzothiazol-2-ylamino)-4-methylsulfanyl- butyric acid
AKOS024302430
2-(benzothiazol-2-ylamino)-4-methylsulfanylbutyricacid
CHEMBL1453118
Q27183582
2-(1,3-benzothiazol-2-ylamino)-4-(methylthio)butanoic acid
DTXSID10349533
SR-01000326221-1
sr-01000326221
SCHEMBL23273787
2-[(1,3-benzothiazol-2-yl)amino]-4-(methylsulfanyl)butanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methionine derivativeAn amino acid derivative resulting from reaction of methionine at the amino group or the carboxy group, or from the replacement of any hydrogen of methionine by a heteroatom. The definition normally excludes peptides containing methionine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency4.46680.044717.8581100.0000AID485294
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
P53Homo sapiens (human)Potency44.66840.07319.685831.6228AID504706
Guanine nucleotide-binding protein GHomo sapiens (human)Potency7.07951.995325.532750.1187AID624288
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]